Matthew P. Frosch, M.D.,Ph.D.
This page shows the publications co-authored by Matthew Frosch and Dennis Selkoe.
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003 Dec 18; 40(6):1087-93.
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 2003 Feb 20; 37(4):583-95.
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 2001 Jul 13; 293(5528):263-9.
Identification of neurotoxic cross-linked amyloid-ß dimers in the Alzheimer's brain. Brain. 2019 05 01; 142(5):1441-1457.
An in vitro paradigm to assess potential anti-Aß antibodies for Alzheimer's disease. Nat Commun. 2018 07 11; 9(1):2676.
Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am J Pathol. 1993 Jan; 142(1):17-24.
Synthetic amyloid beta-protein fails to produce specific neurotoxicity in monkey cerebral cortex. Neurobiol Aging. 1992 Sep-Oct; 13(5):561-7.
Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol. 1992 Jul; 141(1):249-59.
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003 Apr 01; 100(7):4162-7.
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002 May; 160(5):1655-67.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.